9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $130000 | -$19M | 0.0% | -18478.5% | -$18M | — | $3M |
| 2024 | $56000 | -$11M | 0.0% | -30442.9% | -$17M | — | $4M |
| 2023 | $3M | $5M | 3.2% | -99.2% | — | — | $8M |
| 2022 | $34000 | -$10M | 61.8% | -20514.7% | — | $18M | $645000 |
| 2021 | $144000 | -$9M | 86.8% | -5509.0% | — | $13M | $584000 |
| 2020 | $361000 | -$11M | 92.8% | -2797.8% | -$8M | — | $527000 |
| 2019 | $2M | -$12M | 85.9% | -726.8% | -$11M | — | $2M |
| 2018 | $1M | -$8M | 73.9% | -805.5% | -$8M | — | $7M |
| 2017 | $1M | -$7M | 88.0% | -474.6% | -$6M | — | $7M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$7M | — | — | -$5M | — | $25M |
| Dec '25 | $0 | -$3M | — | — | -$6M | — | $3M |
| Sep '25 | $0 | -$5M | — | — | -$4M | — | $9M |
| Jun '25 | $130000 | -$6M | 0.0% | -4280.8% | -$4M | — | $6M |
| Mar '25 | $0 | -$5M | — | — | -$4M | — | $4M |
| Dec '24 | -$14000 | -$3M | 0.0% | 39635.7% | -$5M | — | $4M |
| Sep '24 | $14000 | $1M | 0.0% | -37942.9% | -$3M | $11M | $3M |
| Jun '24 | $51000 | $5M | 0.0% | -7580.4% | -$8M | — | $6M |
| Mar '24 | $5000 | -$15M | 0.0% | -46420.0% | -$2M | — | $9M |
| Dec '23 | $3M | $1M | 1.8% | 7.8% | — | — | $8M |
| Sep '23 | $29000 | $2M | 117.2% | -5044.8% | -$1M | — | $397000 |
| Jun '23 | $7000 | $808000 | 57.1% | -13500.0% | — | — | $261000 |
| Mar '23 | $30000 | $2M | 30.0% | -3206.7% | — | — | $280000 |
| Dec '22 | $8000 | -$3M | 87.5% | -22275.0% | — | $18M | $645000 |
| Sep '22 | $9000 | -$2M | 44.4% | -17222.2% | — | $16M | $466000 |
| Jun '22 | $12000 | -$3M | 50.0% | -13258.3% | — | — | $702000 |
| Mar '22 | $5000 | -$3M | 80.0% | -41040.0% | — | — | $448000 |
| Dec '21 | $27000 | -$2M | 96.3% | -6914.8% | — | $13M | $584000 |
| Sep '21 | $24000 | -$2M | 91.7% | -6975.0% | — | — | $731000 |
| Jun '21 | $37000 | -$2M | 64.9% | -5959.5% | — | — | $615000 |
How the market has priced SER against its own fundamentals since 2024-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Serina Therapeutics, Inc.'s revenue has declined 18.5% per year. These are computed facts, not advice.
As of FY2025, Serina Therapeutics, Inc. reported — of total debt against $3M of cash; operating income covered interest expense -112.8×.
In FY2025, gross margin was —, operating margin -18478.5%, and net margin -14755.4%.
As of Jun '26, Serina Therapeutics, Inc. traded at a price-to-earnings ratio of about 14.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.